Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

@inproceedings{Kim2017UseOA,
  title={Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer},
  author={Dalyong Kim and Yong Sang Hong and Jeong Eun Kim and Kyu-pyo Kim and J S Lee and S. M. Chun and Jihun Kim and Se Jin Jang and Tae Won Kim},
  booktitle={Cancer research and treatment : official journal of Korean Cancer Association},
  year={2017}
}
PURPOSE Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RAS Mutational analysis using a high-throughput genotyping platform (OncoMap) and evaluated extended RAS analysis for predicting cetuximab efficacy in patients harboring wild-type KRAS exon 2 tumors following Sanger… CONTINUE READING